Correcting Gene-based Frontotemporal Dementia, Lisa Deschamps, CEO Aviado Bio
What if we could fix the gene that causes dementia? In this episode, Aviado Bio CEO Lisa Deschamps tells us how her team is working to correct the gene driving many cases of frontotemporal dementia.Â
-------- Â
14:41
--------
14:41
Tuning your own DNA?? Dr. Derek Jantz, Chief Scientific Officer, Tune Therapeutics
What if you could tune your DNA to fix any mistakes? Dr. Derek Jantz from Tune Therapeutics talks about tuning DNA, not just with humans, but stopping the Hepatitis B virus in its tracks.
-------- Â
17:38
--------
17:38
A New Way to Treat Wounds?? Dr. Ned Swanson, Co-Founder, President & Chief Medical Officer, Polarity Bio
Imagine a world where the toughest wounds heal twice as fast, and patients get their lives back sooner than anyone thought possible. Dr. Ned Swanson, the President and Chief Medical Officer of Polarity Bio, tells us about their approach to healing serious, hard-to-treat skin wounds. In early trials, it's twice as effective as the current treatment for diabetic foot ulcers.
-------- Â
15:02
--------
15:02
Treating the Untreatable in Rheumatoid Arthritis! Rob Armstrong, CEO, Artax Biopharma
40% of all rheumatoid arthritis patients do not respond to any of the current drugs. Rob Armstrong, CEO of Artax Biopharma, aims to bring new hope for those patients who've been left without effective treatment options.
-------- Â
17:12
--------
17:12
Treating babies with congenital heart defects... Dr. Joshua Hare, Co-Founder and Chief Scientific Officer, Longeveron
Can you imagine parents expecting a baby, going in for an ultrasound, and finding out that their baby is missing the heart's left ventricle? This week on BioTech Nation, Dr. Joshua Hare, Co-Founder and Chief Scientific Officer of Longeveron, talks about how they are testing the use of stem cells to treat babies born with a serious congenital heart defect.
Welcome to BIOTECH NATION !!! With understandable interviews requiring no background in science, BTN attracts a wide global audience. From everyday people looking for hope in treatments in development, to bioentrepreneurs interested in the experience of their fellow travelers, to venture capitalists looking for possibilities in cutting-edge breakthroughs, to scientists simply interested in the work of others, BioTech Nation is the voice of human endeavor, driving science to new realities for everyone. These interviews are drawn directly from the public radio program, "Tech Nation", which also can be heard in numerous global radio and podcasting venues.
Ireland